% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • solantey Mar 20, 2013 8:48 AM Flag

    Should Be Trading At .30 Currently

    I have to believe that the evaluation from the Swiss lab confirming the positive results of the MANF study are already known to Gerald. I think the positive results were instrumental in bringing Dr. Benedyk "on board".

    This is substantially undervalued. It should be trading in the .30 range currently.

    Jason Napadano's current valuation of .20 excluded attributing any value to Amarantus Diagnostics.

    From the press release:

    Dr. Benedyk is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy. In this role he serves on the Strategic Advisory Board of KemPharm, Inc., is a Director at the Center for Drug Research and Development Ventures, Inc., and is a member of the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membership on the TPI Board of Directors, board positions with TPI portfolio companies, oversight of the TPI operations team, and reviewing investment opportunities in multiple technologies.

    Dr. Benedyk has held executive business development roles at Ascenta Therapeutics, Optimer Pharmaceuticals, Aurora Biosciences (acquired by Vertex Pharmaceuticals), and Elan Pharmaceuticals, where he led partnering efforts for several key clinical-stage products for the treatment of Alzheimer’s Disease, migraine and other neurological indications. He received his Ph.D. in Developmental and Molecular Genetics from The Rockefeller University, and Bachelor of Science degree in Microbiology and Botany from the University of Michigan.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.206+0.006(+3.00%)Feb 10 3:59 PMEST